Payment overview · 2025
General Payments
$578.96
35 reported records · 14 companies
Healthcare provider profile · identity verified
Michael Bogan Evan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · POLAND, OH · NPI 1336123124
Verified facts
What the public records show
CMS Open Payments records show Michael Bogan Evan, M.D. received $578.96 in general payments during 2025 across 35 reported records.
PFIZER INC. accounted for 34.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 298 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $200.48 | 34.6% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.32 | 9.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.00 | 9.3% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $39.51 | 6.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.57 | 6.7% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.97 | 6.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.79 | 5.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.74 | 3.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.89 | 3.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.63 | 3.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.28 | 3.0% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $16.33 | 2.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.90 | 2.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.55 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $578.96 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $188.68 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $181.24 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $55.32 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.61 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.61 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $39.51 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.02 | 2 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $36.97 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $11.80 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 298 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
148 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
298 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 660 | 139 |
| Atorvastatin Calcium | Atorvastatin Calcium | 581 | 138 |
| Metoprolol Succinate | Metoprolol Succinate | 475 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 454 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 414 | 109 |
| Omeprazole | Omeprazole | 397 | 112 |
| Metformin Hcl | Metformin Hcl | 341 | 78 |
| Eliquis | Apixaban | 298 | 47 |
| Gabapentin | Gabapentin | 297 | 74 |
| Simvastatin | Simvastatin | 279 | 75 |
| Lisinopril | Lisinopril | 218 | 53 |
| Furosemide | Furosemide | 206 | 55 |
| Methylprednisolone | Methylprednisolone | 204 | 157 |
| Tamsulosin Hcl | Tamsulosin Hcl | 192 | 51 |
| Azithromycin | Azithromycin | 187 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 36 |
| Donepezil Hcl | Donepezil Hcl | 169 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 35 |
| Jardiance | Empagliflozin | 161 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 38 |
| Synthroid | Levothyroxine Sodium | 148 | 34 |
| Losartan Potassium | Losartan Potassium | 142 | 35 |
| Potassium Chloride | Potassium Chloride | 142 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 134 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 133 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 132 | 29 |
| Meloxicam | Meloxicam | 132 | 31 |
| Clonazepam | Clonazepam | 124 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 118 | 29 |
| Sertraline Hcl | Sertraline Hcl | 118 | 25 |
| Ramipril | Ramipril | 109 | 25 |
| Metformin Hcl Er | Metformin Hcl | 105 | 26 |
| Spironolactone | Spironolactone | 105 | 26 |
| Carvedilol | Carvedilol | 104 | 22 |
| Primidone | Primidone | 104 | 20 |
| Pregabalin | Pregabalin | 103 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 27 |
| Prednisone | Prednisone | 96 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 49 |
| Alprazolam | Alprazolam | 92 | 24 |
| Valsartan | Valsartan | 91 | 21 |
| Allopurinol | Allopurinol | 88 | 21 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 77 | 16 |
| Glipizide | Glipizide | 75 | 22 |
| Mirtazapine | Mirtazapine | 73 | 13 |
| Cefuroxime | Cefuroxime Axetil | 72 | 59 |
| Cephalexin | Cephalexin | 72 | 51 |
| Tramadol Hcl | Tramadol Hcl | 71 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 23 |
| Finasteride | Finasteride | 70 | 14 |
| Alendronate Sodium | Alendronate Sodium | 68 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 66 | 19 |
| Bumetanide | Bumetanide | 65 | 16 |
| Montelukast Sodium | Montelukast Sodium | 65 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 48 |
| Fenofibrate | Fenofibrate | 59 | 12 |
| Atenolol | Atenolol | 58 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 57 | 12 |
| Trulicity | Dulaglutide | 57 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 22 |
| Trazodone Hcl | Trazodone Hcl | 53 | 12 |
| Ezetimibe | Ezetimibe | 52 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Lorazepam | Lorazepam | 43 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | 11 |
| Fluconazole | Fluconazole | 41 | 21 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 40 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Famotidine | Famotidine | 39 | suppressed |
| Glipizide Er | Glipizide | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Naproxen | Naproxen | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 32 | suppressed |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Colchicine | Colchicine | 31 | suppressed |
| Dutasteride | Dutasteride | 31 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 27 | suppressed |
| Metronidazole | Metronidazole | 26 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 13 |
| Nystatin | Nystatin | 24 | 11 |
| Pentoxifylline | Pentoxifylline | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 15 |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Amoxicillin | Amoxicillin | 17 | 11 |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 16 | 16 |
| Guanfacine Hcl | Guanfacine Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $578.96 · 35 records | PFIZER INC. | ACCRUFER, AIRSUPRA, AZMIRO, Auvelity, ELIQUIS, FARXIGA, GEMTESA, Korlym, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, Symbravo, UBRELVY, VOQUEZNA, WAKIX, Wegovy, XIFAXAN, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error